Advertisement
OtherInflammation, Immunopharmacology, and Asthma

First-in-Human Phase 1 Randomized Trial with the Anti-CD40 Monoclonal Antibody KPL-404: Safety, Tolerability, Receptor Occupancy, and Suppression of T-Cell-Dependent Antibody Response

Manoj Samant, John Ziemniak and John F Paolini
Journal of Pharmacology and Experimental Therapeutics September 12, 2023, JPET-AR-2023-001771; DOI: https://doi.org/10.1124/jpet.123.001771
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

OtherInflammation, Immunopharmacology, and Asthma

First-in-Human Phase 1 Trial with KPL-404

Manoj Samant, John Ziemniak and John F Paolini
Journal of Pharmacology and Experimental Therapeutics September 12, 2023, JPET-AR-2023-001771; DOI: https://doi.org/10.1124/jpet.123.001771
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement